Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2018, v. 70, n. 6, p. 832, doi. 10.1002/art.40444
- By:
- Publication type:
- Article
Works matching AU Pileckyte, Margarita
Results: 4
1
2
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2018, v. 70, n. 1, p. 40, doi. 10.1002/art.40336
- By:
- Publication type:
- Article
3
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.
- Published in:
- FASEB Journal, 2008, v. 22, n. 7, p. 2214, doi. 10.1096/fj.07-105627
- By:
- Publication type:
- Article
4
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
- Published in:
- Arthritis Research & Therapy, 2018, v. 20, n. 1, p. N.PAG, doi. 10.1186/s13075-018-1676-y
- By:
- Publication type:
- Article